MedTrace Logo

TARGTEPO Treatment for Anemia in PD US Trial

NCT02468414 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2022-03-28

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients

Conditions

  • Anemia of End Stage Renal Disease

Interventions

BIOLOGICAL

MDGN201 TARGTEPO

MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)

BIOLOGICAL

MDGN201 TARGTEPO

MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)

Sponsors & Collaborators

  • Medgenics Medical Israel Ltd.

    collaborator INDUSTRY

  • Aevi Genomic Medicine, LLC, a Cerecor company

    lead INDUSTRY

Principal Investigators

  • Shany Blum, MD PhD · Medgenics Medical Israel Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-05-31
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02468414 on ClinicalTrials.gov